Elevance Health (ELV) Stock
Key stats
- Market cap
- $92.79B
- Price / Earnings ratio
- 18.1x
- EPS (TTM)
- $23.62
- Volume
- Loading
- 52-week high
- $450.69
- 52-week low
- $274.84
- Dividend yield
- 1.60%
- Dividend amount (latest)
- $1.72
- EPS vs analyst estimate
- +21.6%Q3 FY25 · $6.03 vs $4.96
Source: third-party data provider, as of November 13, 2026
EPS estimate: analyst consensus
Compare with ELV
Recent news

Elevance Health (ELV) Is Up 2.73% in One Week: What You Should Know
Elevance Health (ELV) Is Up 2.73% in One Week: What You Should Know
ELV

Implied Volatility Surging for Elevance Health Stock Options
Implied Volatility Surging for Elevance Health Stock Options
ELV

ELV vs. RVTY: Which Stock Is the Better Value Option?
ELV vs. RVTY: Which Stock Is the Better Value Option?
ELV

Elevance: 3 Key Takeaways for Long-Term Investors
Elevance: 3 Key Takeaways for Long-Term Investors
ELV
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 54.85
- MACD 12/26/9
- 3.44
- EMA 9 of MACD
- 4.05
- MACD histogram
- -0.61
- SMA 50
- $414.62
- Price above SMA 50
- EMA 50
- $415.72
- Price above EMA 50
- SMA 200
- $374.65
- Price above SMA 200
- EMA 200
- $380.83
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Buy
Based on 8 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of $5.61 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Elevance Health (ELV) Is Up 2.73% in One Week: What You Should Know
Elevance Health (ELV) Is Up 2.73% in One Week: What You Should Know
ELV

Implied Volatility Surging for Elevance Health Stock Options
Implied Volatility Surging for Elevance Health Stock Options
ELV

ELV vs. RVTY: Which Stock Is the Better Value Option?
ELV vs. RVTY: Which Stock Is the Better Value Option?
ELV

Elevance: 3 Key Takeaways for Long-Term Investors
Elevance: 3 Key Takeaways for Long-Term Investors
ELV

2 Healthcare Stocks to Buy After Crushing Q3 Earnings Expectations: ELV & ISRG
2 Healthcare Stocks to Buy After Crushing Q3 Earnings Expectations: ELV & ISRG
ELV

Elevance Health, Inc. (ELV) Hits Fresh High: Is There Still Room to Run?
Elevance Health, Inc. (ELV) Hits Fresh High: Is There Still Room to Run?
ELV

ELV Beats Q3 Earnings Estimates on Carelon Strength, Raises 2026 Outlook
ELV Beats Q3 Earnings Estimates on Carelon Strength, Raises 2026 Outlook
ELV

What Elevance Health (ELV) Said on Its Q3 Earnings Call
What Elevance Health (ELV) Said on Its Q3 Earnings Call
ELV

Compared to Estimates, Elevance Health (ELV) Q3 Earnings: A Look at Key Metrics
Compared to Estimates, Elevance Health (ELV) Q3 Earnings: A Look at Key Metrics
ELV

Elevance Health (ELV) Surpasses Q3 Earnings and Revenue Estimates
Elevance Health (ELV) Surpasses Q3 Earnings and Revenue Estimates
ELV
News tone: automated (AI) classification of the article's content, not a price prediction.
About Elevance Health
Elevance Health brings together the concepts of elevate and advance, exemplified by our bold purpose of improving the health of humanity. We are a health company dedicated to making real progress toward improving the health of the people and communities we serve.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Ms. Gail Koziara Boudreaux | President, CEO & Director | 1961 |
| Mr. Mark Bradley Kaye | Executive VP & CFO | 1980 |
| Mr. Peter David Haytaian Esq. | Special Advisor | 1970 |
| Mr. Charles Morgan Kendrick Jr. | EVP and President of Commercial & Specialty Health Benefits | 1966 |
| Ms. Felicia Farr Norwood | Executive VP & Chief Health Benefits Officer | 1960 |
| Mr. Scott Wayne Anglin | SVP, Treasurer & Chief Investment Officer | — |
| Mr. Ronald William Penczek | Senior VP, Controller & Chief Accounting Officer | 1965 |
| Mr. Nathan Allen Rich | Vice President of Investor Relations | — |
| Ms. Erin M. Wessling | Executive VP & Chief Legal Officer | 1978 |
| Ms. Julie Goon | Senior Vice President of Public Affairs | — |
Fundamentals
Valuation
Profitability
Trading
Dividend
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 54.85
- MACD 12/26/9
- 3.44
- EMA 9 of MACD
- 4.05
- MACD histogram
- -0.61
- SMA 50
- $414.62
- Price above SMA 50
- EMA 50
- $415.72
- Price above EMA 50
- SMA 200
- $374.65
- Price above SMA 200
- EMA 200
- $380.83
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
8 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $406.00
- Average
- $472.13
- High
- $523.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -6.5 | +14.6 | ||||||||||
| 2022 | -5.1 | +3.0 | +8.8 | +0.5 | +2.5 | -3.3 | -1.8 | +3.0 | -7.3 | +16.3 | -2.1 | -2.3 |
| 2023 | -0.4 | -5.8 | -2.0 | -1.6 | -5.2 | -4.3 | +6.1 | -5.5 | -1.6 | +2.2 | +7.4 | -2.4 |
| 2024 | +3.1 | +1.2 | +3.9 | +2.4 | +2.6 | -0.2 | -0.5 | +4.6 | -7.5 | -20.6 | -1.7 | -10.1 |
| 2025 | +8.2 | -2.0 | +10.0 | -2.8 | -6.0 | +3.2 | -28.5 | +16.0 | +0.2 | -4.6 | +8.0 | +6.3 |
| 2026 | -2.4 | -6.4 | -0.4 | +26.1 | +5.5 | -4.0 | -9.7 | +2.6 | -3.5 | +10.1 | +3.8 |



